Gravidin is a potent phospholipase A 2 inhibitor that may contribute to the maintenance of human pregnancy. The aims of this study were to determine firstly, the site of gravidin synthesis within placental membranes and secondly, whether the antiprogestin compound, RU486, regulates synthesis. Membrane explants were taken from placentae, dissected and cultured in the presence of RU486, progesterone or inhibitors of DNA or protein synthesis and gravidin production was measured by a specific enzyme-linked immunosorbent assay. Production of gravidin was consistently greatest from choriodecidua compared with amnion and decidua. The antibiotics, cycloheximide and actinomycin D inhibited production of gravidin. The progesterone receptor antagonist RU486 at 10 -8 and 10 -7 M reduced gravidin production to 55 and 39% of the control value in membranes cultured after and before the onset of labour respectively. Progesterone at 10 -6 M stimulated gravidin production by 47% after the onset of labour. The increase in gravidin production was correlated with progesterone concentration (r ϭ 0.47, F ϭ 6.38, P ϭ 0.019) in labour tissue. We conclude that the data are consistent with the hypothesis that gravidin production may be partially regulated by progesterone.
Introduction
Inhibition of prostaglandin synthesis by pharmacological agents plays a major role in the control of processes as diverse as inflammation and parturition. The endogenous mechanisms of regulation of prostaglandin synthesis remain undefined but probably involve the inhibition of phospholipase A 2 , (EC3.1.1.4), a key enzyme in the regulation of prostaglandin synthesis. Abortion can be induced with prostaglandin treatment at any time in pregnancy after implantation and RU486 (mifepristone), which is able to cause abortion, increases prostaglandin concentrations (Haluska et al., 1994) . RU486 is particularly effective after the uterus has been primed with low dose prostaglandins implying increased sensitivity to prostaglandins (Avrech et al., 1991) .
We have partially characterized a phospholipase inhibitor that we have named gravidin (for review see Wilson, 1993a) . It is an 80 kDa protein that has N-terminal sequence homology with the secretory component of immunoglobulin (IgA) (Wilson and Christie, 1991) . However, gravidin is not identical to IgA secretory component as it can be distinguished from it with polyclonal antibody (Wilson et al., 1994) and has a slightly higher molecular weight on a sodium dodecyl sulphate (SDS) gel (Cleveland et al., 1991) . Gravidin is therefore defined as the secretory component present in human amniotic fluid. Secretory component from colostrum has been shown to inhibit phospholipase A 2 activity (Wilson and Christie, 1991) . Gravidin inhibits pork pancreas phospholipase A 2 activity in vitro and also the release of arachidonic acid from lymphocytes, decidual cells, endometrial cells and other non-transformed cells at a concentration of 5ϫ10 -9 M. Using an enzyme-linked immunosorbent assay (ELISA) for gravidin, we found elevated serum gravidin/ secretory component concentrations in pregnant women .
Previous work has suggested that the site of gravidin synthesis may be the placental membranes (Wilson et al., 1986) . We postulated that the interaction between RU486 and prostaglandins may occur through regulation of gravidin synthesis. We therefore set out to determine the site of gravidin synthesis and the effect of RU486 and progesterone upon its production.
Materials and methods

Collection of membranes
Following a protocol approved by the Tayside Ethical Committee, placentae were collected within 15 min of delivery from women who delivered vaginally by spontaneous labour (IL) at term, and from women who were delivered at term by elective Caesarean section (NIL). The mean age of delivery was 38.6 Ϯ 0.33 weeks and 39.3 Ϯ 0.34 weeks (mean Ϯ SEM) for elective sections and normal deliveries respectively. Membranes were washed well to remove traces of blood and then separated by blunt dissection into amnion, choriodecidua and decidua. The choriodecidua was mainly chorion, but contamination with decidua could not be excluded. After thorough washing in G199 medium (Gibco, Paisley, UK) containing Hanks' salts, the tissue was cut with scissors into pieces of approximately equal size (~0.05 g w/w) and incubated at 37°C in an atmosphere of 95% air, 5% CO 2 , in 24-well plates containing 2 ml of medium/well (G199 with Earle's salts, plus penicillin and streptomycin). After 6 h the medium was removed and replaced by treatment or control medium. Treatments RU486 (mifepristone) was a generous gift from Roussel-Ucclaf, Paris, France. Actinomycin D, cycloheximide, progesterone, dexamethasone and cortisol were obtained from Sigma Chemicals (Poole, Dorset, UK).
Progesterone, cycloheximide and RU486, cortisol and dexamethasone were dissolved in ethanol to form stock solutions of 10 -3 M and controls with appropriate dilutions of ethanol were used throughout. All incubations with test substances were performed for 13 h. Six replicate pieces of tissue were set up for each treatment and compared with untreated control tissue pieces from the same placenta. The 6-19 h interval was used in investigations as this was judged sufficiently distant from dissection trauma, yet close to time of tissue acquisition. The medium obtained at 19 h was centrifuged at 10 000 g for 5 min at room temperature to remove cell debris. Actinomycin D (at 1 or 50 µg/ml) or cyclohexamide (at 10 or 100 µg/ml) were included in the incubation medium of some groups of explants from the start of treatment.
Western Blotting of secreted tissue products
Medium from incubated choriodecidua was concentrated to one tenth its original volume and protein precipitated with 100% ammonium sulphate after the addition of bovine serum albumin (0.05 mg/ml). The precipitate was dissolved in buffer (0.1 M Tris-HCl, pH 7.4) and run on a 7% SDS gel according to Laemmli (1970) and using prestained molecular weight markers from BioRad (Hemel Hempstead, UK). Several gels were blotted onto nitro-cellulose membranes and developed with either polyclonal (Sigma S1640, raised in goat) or monoclonal antibody from Sigma (I66350, 1:1000 dilution in blocking buffer) or our in-house antigravidin antibody (raised in rabbit against a purified band of gravidin cut out from a polyacrylamide gel). After blotting, membranes were rinsed in buffer (Tris-HCl 50 mM, pH 7.4) and then in blocking buffer (Tris-HCl 10 mM, NaCl 150 mM, 1% Marvel, pH 7.4)
Gravidin measurement
Gravidin was measured using a sandwich ELISA assay as described previously (Wilson, 1993b) . Anti-secretory component antibody was used in the assay for two reasons: firstly, there is no commercial source of gravidin for use as standard and in-house gravidin is in short supply; and secondly, anti-gravidin antibody does not recognize commercially obtained secretory IgA (from breast milk). On the other hand, anti-secretory component antibody detects both gravidin and secretory component. Briefly, 96-well plates were coated with a monoclonal antibody to secretory component Sigma catalogue number S1640 (1:1000 dilution in Tris-HCl 10 mM, NaCl 150 mM and incubated overnight with 100 µl choriodecidua media (1:8000 dilution in Tris buffer (50 mM, pH 7.4) containing 0.15 M NaCl. The second antibody was polyclonal anti-secretory component antibody from Sigma (S1640), and it was detected with an anti-IgG peroxidasebound antibody. Intra-assay variation was Ͻ10% and inter-assay variation was 13%. Serum IgA from colostrum was used as standard and the concentration ranged from 5 µg to 100 ng/ml. The lowest detectable level of standard was 50 ng/ml.
Protein determinations
Tissue was sonicated in 0.1 M NaOH until completely dispersed (as indicated by no precipitate on centrifugation) and an aliquot of the supernatant was assayed for protein determination using the method of Bradford (1976) . Choriodecidua, amnion and decidua were dissected from fresh placentae and incubated under the conditions described in the Materials and methods section. Medium was replaced after 6 h and the gravidin concentration of fresh medium measured following a further 13 h incubation. Protein was determined by the Bradford assay and results are shown as mean Ϯ SEM. The number of placentae contributing to each point is shown in brackets.
Results
Production of gravidin by placental membranes
Western blotting of chorion medium showed that the monoclonal anti-secretory component antibody recognized a single protein in the medium. This had the same molecular weight as the secretory component band found in amniotic fluid and a slightly higher molecular weight than the secretory component of colostrum. The protein was detectable with our anti-gravidin antibody which did not detect secretory component from colostrum. The protein in chorion medium was therefore identified as gravidin (Wilson et al., 1994) .
The medium was further tested by double immunodiffusion using polyclonal anti-secretory component antibody in the centre well. A single precipitin band was detected from the chorion medium which was different from the two precipitin bands detected in colostrum and which corresponded with secretory component and secretory IgA.
To determine whether placental membranes were a source of gravidin, the separated membranes (amnion, choriodecidua and decidua) from four placentae were compared for gravidin production. Figure 1 shows that choriodecidua produced more gravidin than other tissues on a unit protein basis but the difference was not statistically significant. However, in three out of four placentae, both choriodecidua and decidua produced more gravidin than amnion (Table I) , choriodecidual membranes were therefore used in subsequent studies. When gravidin production was compared in tissue from IL and NIL deliveries, there was a reduction in gravidin in media from IL tissues, but this was not statistically significant (Figure 2 ). Figure 2. Gravidin production by choriodecidua before (following elective Caesarean) and after the onset of labour. Pieces of choriodecidua were prepared and cultured under the conditions described in the Materials and methods section. The medium was replaced after 6 h incubation and the incubation continued for a further 13 h after which gravidin concentrations were measured by enzyme-linked immunosorbent assay. Results are expressed as mean Ϯ SEM and the numbers in brackets are the numbers of placentae.
Treatment with actinomycin D and cyclohexamide
To determine whether synthesis and secretion of gravidin were taking place, actinomycin D (an inhibitor of transcription) and cycloheximide (an inhibitor of translation) were added separately to the incubations. Actinomycin D (1 µg/ml) reduced gravidin production by 38% whereas cycloheximide (10 µg/ ml) reduced gravidin production by 42% over 13 h ( Figure  3 ). The effect of antibiotics was significant (P Ͻ 0.02; twoway analysis of variance), but the difference between antibiotics was not significant (Figure 3 ).
Treatment with RU486
Addition of RU486 to culture media resulted in a decrease in gravidin production as shown in Figure 4 . Because of the variation between patients in the amount of gravidin produced, the results are expressed as a percentage of control production for each tissue. At a concentration of 10 -8 M, RU486 reduced gravidin production by 31% in NIL tissue and 55% in IL tissue. In a two-way analysis of variance, the difference between IL and NIL tissue was not significant, but was significant between RU486 concentrations (F ϭ 5.58; P ϭ 0.003). Using Dunnett's multiple comparison post-hoc test, both RU486 concentrations inhibited gravidin production significantly compared with the control (P Ͻ 0.01). 
Treatment with progesterone
To determine whether progesterone had the opposite effect to RU486, the dependence of gravidin production on progesterone was investigated. In both IL and NIL tissues, addition of progesterone o the medium induced a dose-dependent increase in gravidin production but this only attained significance in the IL tissue ( Figure 5) . At the highest concentration tested (10 -6 M), gravidin production was increased by 47%. There was a positive correlation between progesterone concentration and gravidin production and this was significant for the IL tissue (Pearson's r ϭ 0.47, F ϭ 6.38, P ϭ 0.019). For 10 -6 M progesterone versus the control, P ϭ 0.051.
Treatment with glucocorticoid
The effect of glucocorticoid additions was investigated. Cortisol and dexamethasone were added to the incubation medium of not-in-labour choriodecidua at concentrations of 10 -6 M. Gravidin production was inhibited to 71 Ϯ 32% and 35 Ϯ 9.2% (n ϭ 3) of the control respectively. The inhibition by dexamethasone was significant (P ϭ 0.02).
Discussion
RU486 increases prostaglandin concentrations; this may occur through inhibition of the enzyme prostaglandin dehydrogenase (Kelly and Bukman, 1990) . However, it is generally agreed that the observed increases in prostaglandin production are insufficient for induction of labour (Kelly, 1992) . Hence, inactivation of prostaglandin dehydrogenase may not be the only mechanism whereby RU486 causes induction. A different explanation is that RU486 may stimulate prostaglandin syn- thesis through inhibition of a natural inhibitor of prostaglandin production. In a previous study, Wilson (1993) reported the discovery of gravidin, an endogenous inhibitor of phospholipase A 2. In this study, we tested the hypothesis that RU486 would decrease gravidin production by cultured placental membranes. The detection in chorion culture medium, by Western blotting, of a single protein band with the same molecular weight as secretory component from amniotic fluid, confirmed that the chorion product detected by ELISA was gravidin. Further confirmation was provided by blotting with the antigravidin antibody which does not detect secretory component from breast milk (Wilson et al., 1994) .
When placental tissues were compared, the highest gravidin production was from choriodecidua, in comparison with decidua and amnion This is in accordance with previous work that investigated the activity of gravidin from fetal membranes and found greatest activity in chorion medium (Wilson et al., 1989) .
The production of gravidin was reduced to 60% in the presence of actinomycin D (1 µg/ml) and to 58% in the presence of cycloheximide indicating that synthesis of gravidin takes place in the choriodecidua (Figure 3 ). There may be considerable storage of gravidin within the choriodecidua as production was not decreased by incubation with higher concentrations of the inhibitors. An alternative explanation is that the antibiotic effect was limited, perhaps by the tissue structure or compartmentalization. Addition of RU486 to the culture media caused a substantial inhibition of gravidin production (Figure 4) . Concentrations of 10 -8 M RU486 were effective in reducing production to 45% of the control in tissue taken after the onset of labour. This is of the same order as reported serum concentrations following pharmacological administration of RU486. Pharmaco-kinetic investigations have shown that 2 days after a 600 mg dose of RU486, serum values are of the order of 3 µM (Heikinheimo et al., 1990 ) of which it is estimated that 98% is bound to α1-acid glycoprotein. This would leave an effective serum value of 2ϫ10 -8 M in women receiving 600 mg of RU486.
Surprisingly, progesterone was not as effective at stimulating, as RU486 was at inhibiting, gravidin production. However, a dose-response curve was obtained for IL choriodecidua and, compared with the control, a significant stimulation was found with a concentration of 10 -6 M progesterone ( Figure 5 ). It is possible that the effect of RU486 was not progesterone-related (e.g. acting through inhibition of the glucocorticoid receptor). It is also possible that progesterone concentrations in the tissue were already high and the steroid was not easily reduced in the control tissue. A different explanation is that the effects of progesterone on gravidin synthesis are somehow impaired at term.
The effects of progesterone and corticosteroids were not the same (see Results), indicating that RU486 did not act through the glucocorticoid receptor. In fact, the response to dexamethasone was similar to RU486 at 10 -6 M although a lower concentration of dexamethasone was not investigated.
It has been suggested that RU486 may cause induction of labour through inhibition of prostaglandin dehydrogenase. Kelly and Bukman (1990) showed reduced metabolism of prostaglandins in chorion from guinea pigs given the high dose of 10 mg/animal. Subsequent immunohistochemical studies using lower doses of RU486 showed an insignificant reduction in chorion prostaglandin dehydrogenase conentrations, but a marked reduction in decidual concentrations (Cheng et al., 1993) .
Gravidin is a potent inhibitor of phospholipase activity (Wilson et al., 1989) . Inhibition of gravidin synthesis would not normally cause an increase in prostaglandin production unless a stimulator was present. RU486 has been shown to increase prostaglandin synthesis in several systems although the results have been variable and quite modest (Kelly, 1992) . This is consistent with RU486 inhibition of a phospholipase inhibitor. Whether prostaglandin production did increase would depend on the presence of stimulators or the amount of damage to the tissue during dissection. The observation that the effect on prostaglandin synthesis is greater in vitro than in vivo (Kelly, 1992) , is consistent with such a hypothesis.
In summary, the effect of RU486 on gravidin production is consistent with the observed stimulation of prostaglandin synthesis by fetal membranes and may provide a mechanism.
